Industry responds to Viehbacher's departure

On the third-quarter earnings call of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), CEO Leonard Schleifer addressed the company's relationship with Sanofi (Euronext:SAN; NYSE:SNY) following the ouster of CEO Christopher Viehbacher.

"We expect the relationship to continue without interruption and unabated as we advance our joint pipeline, including three Phase III antibodies, through clinical trials into commercialization," Schleifer said. He added he will meet this week with Sanofi interim CEO Serge Weinberg. ...